Johnson & Johnson has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 27, 2022 ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, reported that the company will be presenting at the Jefferies London Healthcare Conference, which is taking place in London from November 15-17, 2022 (Press release, ImmunityBio, OCT 27, 2022, View Source [SID1234622475]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A replay of the presentation will be available by visiting the "Events" section of the ImmunityBio website and will be archived for 90 days.

On October 27, 2022 Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, reported that Bristol Myers Squibb (NYSE:BMY) has opted to extend the term of the parties’ multi-year strategic collaboration for the discovery and development of novel, regulated cell therapies that utilize Obsidian’s cytoDRiVE technology for the controlled expression of the immune enhancer CD40L (Press release, Obsidian Therapeutics, OCT 27, 2022, View Source [SID1234622474]). Today’s announcement builds on the existing relationship between Obsidian and Bristol Myers Squibb, initiated in 2019, and follows the first opt-in decision by Bristol Myers Squibb in 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to extend our productive strategic partnership with Bristol Myers Squibb, an industry leader in the field, to advance next-generation cell therapies to patients with solid tumors and other malignancies," said Paul K. Wotton, Ph.D., Chief Executive Officer of Obsidian Therapeutics. "This announcement comes at an exciting time for Obsidian as our own lead program using cytoDRiVE technology enters the clinic."

This multi-year collaboration extension provides Bristol Myers Squibb with the exclusive option to in-license worldwide rights for cell therapy candidates incorporating Obsidian’s cytoDRiVE technology to control the expression of CD40L for the treatment of cancer. Under the terms of the agreement, Obsidian is eligible to receive potential future milestone and royalty payments.

On October 6, 2022 Prestige Biopharma Limited, a Singapore-based biopharmaceutical company, reported that the company is attending the 2022 Biosimilar Medicines Conference which takes place in Brussels, Belgium, on October 6 and 7 (Press release, Prestige BioPharma, OCT 27, 2022, View Source [SID1234622473]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Biosimilar Medicines Conference by Medicines for Europe (MfE) aims to facilitate discussion on existing challenges and future opportunities for biosimilar medicine policy and pharmaceutical legislation. The MfE represents the pharmaceutical companies supplying the largest share of medicines across Europe. According to the association, its members currently supply over 67% of all medicines in Europe.

This year’s conference is held in person after three years since COVID-19 pandemic. Speakers and panellists will explore how to turn the Pharmaceutical Strategy aim to ensure better access and affordability into concrete biosimilar medicine policy measures.

At the conference, many former and current members of European Medicines Agency (EMA) will be speakers and address biosimilar medicine policies. Prestige Biopharma plans to actively engage in discussions on regulations and build network, while seeking opportunities for collaboration with major biopharmaceuticals in Europe.

Dr. Susanne Schmidt, Director of Alliance & Portfolio Management in Prestige Biopharma, will participate in the conference. Dr. Schmidt had served as Senior Director of Global/International Business Development at Pfizer and has 25 years of experience in the biopharmaceutical industry, working for multiple leading pharmaceuticals.

Dr. Schmidt commented: "The healthcare systems and policies in the European market vary from country to country. This conference, which brings together pharmaceutical experts from different countries in Europe, provides a good opportunity for in-depth study and understanding on the European market. We also plan to strengthen our presence in the European market by participating in more conferences held in individual European countries and introducing our pipeline portfolio and R&D results."

On October 27, 2022 Monteris Medical, a private medical technology company dedicated to becoming the technology leader in minimally invasive brain surgery, reported it has secured $73 million in financing including $35 million in new Series D equity and a $38 million debt facility (Press release, Monteris Medical, OCT 27, 2022, View Source [SID1234622472]). The equity financing was led by new investor, InnovaHealth Partners, and was supported by existing lead investor, Birchview Capital. The debt facility, provided by Madryn Asset Management, LP, extended $28 million at closing, with the option to draw an additional $10 million upon the achievement of certain milestones. The proceeds will be used to support important market adoption, clinical research and technology programs and will permit the company to refinance its current obligation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Brain tumor and drug-resistant epilepsy patients and their physicians are looking for less invasive options when making their treatment decisions," said Martin J. Emerson, Monteris Medical’s president and chief executive officer. "NeuroBlate has been proven to offer a less invasive option for patients considering open brain surgery and is also a valuable minimally invasive tool to address surgical locations in the brain that are not accessible with more invasive traditional methods. The Monteris Medical team is pleased to add InnovaHealth and Madryn as financial partners, allowing us to further expand our efforts to bring the value of the NeuroBlate technology to more physicians and the patients we collectively serve."

The proceeds of this financing will be used to continue to support the rapid adoption of Monteris Medical’s NeuroBlate System, an MR-guided laser ablation system that allows for a minimally invasive surgical alternative to open craniotomies. The NeuroBlate System is currently installed in more than 100 hospitals in the United States and Canada and is actively used in minimally invasive treatment approaches for patients with drug-resistant epilepsy, primary and metastatic brain tumors, and radiation necrosis. These proceeds will also be used to continue ongoing clinical research, including exciting work in adjuvant immunotherapies, and technology advancement projects for the NeuroBlate System.

"Monteris Medical’s NeuroBlate technology and the company’s increasing depth of clinical evidence are transforming how physicians and their patients think about brain surgery. We are proud to support the expansion of this important technology," said Mortimer "Tim" Berkowitz III, InnovaHealth’s president and chief executive officer.